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Abstract
Huntington’s disease (HD) is characterised by progressive symptoms including cognitive deficits and sleep/wake disturbances
reflected in an abnormal electroencephalography (EEG). Modafinil, a wake-promoting and cognitive-enhancing drug, has been
considered as a treatment for HD. We used HD (R6/2) mice to investigate the potential for using modafinil to treat sleep-wake
disturbance in HD. R6/2 mice show sleep-wake and EEG changes similar to those seen in HD patients, with increased rapid eye
movement sleep (REMS), decreased wakefulness/increased non-REMS (NREMS), and pathological changes in EEG spectra,
particularly an increase in gamma power. We recorded EEG from R6/2 and wild-type mice treated with modafinil acutely (with
single doses between 25 and 100mg/kg; at 12 and 16weeks of age), or chronically (64mg/kgmodafinil/day from 6 to 15weeks).
Acutely, modafinil increased wakefulness in R6/2 mice and restored NREMS to wild-type levels at 12 weeks. It also suppressed
the pathologically increased REMS. This was accompanied by decreased delta power, increased peak frequency of theta, and
increased gamma power. At 16 weeks, acute modafinil also restored wakefulness and NREMS to wild-type levels. However,
whilst REMS decreased, it did not return to normal levels. By contrast, in the chronic treatment group, modafinil-induced
wakefulness was maintained at 15 weeks (after 9 weeks of treatment). Interestingly, chronic modafinil also caused widespread
suppression of power across the EEG spectra, including a reduction in gamma that increases pathologically in R6/2 mice. The
complex EEG effects of modafinil in R6/2 mice should provide a baseline for further studies to investigate the translatability of
these result to clinical practice.
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Introduction
Huntington’s disease (HD) is a complex progressive ge-
netic neurodegenerative disorder characterised by motor,
cognitive, and affective symptoms [1]. Disturbances of
sleep-wake behaviour, including sleep fragmentation [2,
3], abnormality of rapid eye movement sleep (REMS)
[4, 5], and daytime sleepiness [6, 7] are widespread
problems in HD patients that frequently appear early in
the course of the disease [8, 9]. Pathological EEG spectral
abnormalities are also seen in HD patients [3, 9, 10].
Alterations of the sleep-wake cycle and electroenceph-
alogram (EEG) found in HD patients are recapitulated in a
number of HD mouse models, including the transgenic
lines of R6/2 [11, 12], R6/1 [13, 14], and Q175 [15–17]
mice. We used the R6/2 line for our studies [18]. These
mice show a phenotype mirroring important symptoms
seen in HD patients, including deteriorating motor and
cognitive functions [19, 20]. Previous studies show that
R6/2 mice have fragmented sleep, accompanied by abnor-
mal REMS across the day/night [11, 12]. R6/2 mice also
show progressive changes in quantitative EEG (qEEG), in
particular a pathological increase in gamma oscillation
power [11, 12].
It has been suggested that disruption of sleep contributes to
cognitive decline in HD [21–23]. Thus, treatments aimed at
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improving the sleep-wake pattern in HD patients may also
have a beneficial knock-on effect on cognitive symp-
toms of the disease. We showed previously using a
combination of modafinil (Provigil) and alprazolam that
treating sleep-wake deficits in R6/2 mice has a benefi-
cial effect on cognitive performance and arousability [9,
21]. To date, however, only one study has examined the
effect of modafinil on mood and cognition in HD pa-
tients [24]. In that study, although modafinil increased
alertness, it did not improve cognitive function.
However, the effect of only a single dose of modafinil
was used. Given that HD patients may respond to drugs
differently from normal subjects, and that modafinil is
used as a cognitive enhancer in both normal and patient
groups (for references, see [25]), modafinil remains an
interesting candidate for treating sleep-wake disorder in
HD [26].
Modafinil is a wake-promoting agent most widely used for
treating excessive daytime sleepiness in several neuropsychi-
atric conditions including narcolepsy [27] and Parkinson’s
disease [28]. Modafinil evokes its robust wake-promoting ef-
fect in the brain by increasing the level of dopamine, norepi-
nephrine, glutamate, serotonin, histamine, and hypocretin/
orexin whilst decreasing the release of GABA [29]. It is also
a putative cognitive enhancer although in this respect the lit-
erature is controversial [25, 30]. It improves memory [31],
executive function [32], and increases alertness and response
accuracy in healthy subjects [25]. Importantly, the cognitive
enhancer effect of modafinil has also been reported in a num-
ber of different neurological conditions including schizophre-
nia [33, 34] and attention deficit hyperactivity disorder [35].
Modafinil has also been shown to be effective when given as
an adjunct to standard treatment for treating mood disorders
[36, 37]. This is particularly relevant in HD, since low mood
and depression occur in a considerable number of patients
[38]. Moreover, pre-symptomatic HD gene–positive individ-
uals with subjective sleep problems have shown significantly
poorer neuropsychiatric outcomes compared to those not
reporting sleep problems [23]. Thus, targeting sleep-wake dis-
order with a drug that may also improve cognitive function
would potentially be doubly beneficial.
Here we investigate the acute effect of modafinil on sleep
and wakefulness at different stages of disease in R6/2 mice.
We also administered modafinil chronically for 9 weeks to
determine if there was any long-term effect of modafinil on
the progression of sleep-wake abnormalities in HD mice. We
found that acutely modafinil was wake-promoting in R6/2
mice and reduced the pathologically increased REMS, al-
though the effect waned as the disease progressed.
Interestingly, when given chronically, modafinil maintained
its wake-promoting effect to end stage, and reduced the path-
ologically increased gamma oscillations, an effect that
persisted after washout.
Materials and Methods
Ethical Statement
All experiments were conducted under the authority of the United
Kingdom Animals (Scientific Procedures) Act 1986 Amendment
Regulations 2012, and with the approval of the University of
Cambridge Animal Welfare and Ethical Review Body.
Animal Numbers and Husbandry
Male R6/2 mice and their wild-type (WT) littermates (C57/
BL6J) were taken from a colony established at the University
of Cambridge. Tail snips were taken at 3 weeks of age for
genotyping and CAG repeat sizing (Laragen, Los Angeles,
CA). CAG repeat lengths were measured by GeneMapper
software (Life Technologies, NY). R6/2 mice had a mean
CAG repeat length of 250 ± 1 (n = 52).
Two experiments were conducted. (For an overview of the
timeline and drug administration protocol, see Fig. S1 and
below.) In the acute experiment, single doses of modafinil
were given to 10 R6/2 and 11 WT mice. One R6/2 mouse
died from its disease before completion of the late-stage
(15–17 weeks) treatments, one WT mouse lost its EEG/
EMG implant and was euthanized before completing the
study, and one WT mouse died unexpectedly of unknown
causes. Due to the cross-over design of the study, we excluded
all recordings of these mice from the data analysis. In total,
9/11 WT and 9/10 R6/2 mice completed all cross-over treat-
ments and EEG/EMG recordings. In the chronic experiment,
modafinil was administered to 20 R6/2 and 11 WT mice.
During the study, one R6/2 mouse died from its disease, and
one R6/2 mouse lost its EEG/EMG implant and was eutha-
nized before completing the study. Thus, 18/20 R6/2 and 11/
11 WT mice completed the chronic modafinil experiment and
were used for the analysis.
After the EEG/EMG implant surgery, animals were housed
individually in cages within sound-attenuating chambers.
They were kept under a 12:12-h light–dark cycle (30 lx
daylight-type fluorescent tubes with lights on at 23:00), at
constant temperature (22 ± 1 °C) and humidity (55 ± 10%).
Food and water were available ad libitum. R6/2 mice also
received a single portion of soft mash each morning (made
by soaking chow pellets in hot water), with an additional por-
tion added later in the day for mice aged > 12 weeks. Bedding
was changed as needed, approximately once a week for WT
mice and twice a week for R6/2 mice.
EEG/EMG Implantation Surgery
All mice were implanted with EEG and EMG electrodes un-
der isoflurane anaesthesia (1.5–2% in 2 l/m oxygen) as de-
scribed previously [11]. Briefly, gold-plated stainless steel
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screw electrodes were placed epidurally above both left and
right hemispheres positioned over the frontal (1.5 mm lateral
and 1.0 mm anterior to bregma) and parietal (1.5 mm lateral
and 1.0 mm anterior to lambda) cortex, for fronto-parietal
EEG recordings. EMG signals were acquired from the neck
extensor muscles via a pair of stainless steel spring wires
(Plastics One Inc., Roanoke, VA). After an 8–10-day recovery
period, the mice were connected to the recording cables, and
remained connected to the cables throughout the study. The
recording cables allowed free movement within the cage.
EEG/EMG Recordings
Following a 12-day acclimatisation period, we began the treat-
ment program. We recorded EEG and EMG signals (Pinnacle
Technology, Lawrence, KS) for 24 h after each treatment
started at 11 am (at light off). The EEG/EMG signals were
amplified and filtered (EEG, 0.5–100 Hz; EMG, 35 Hz high
path filter [HPF]) by head-mounted preamplifiers and ampli-
fiers (8202-DSL and 8206-SL, respectively; Pinnacle
Technology, Lawrence, KS). EEG/EMG data were recorded
using Vital Recorder software (Kissei Comtec, Matsumoto,
Japan) after analogue-to-digital conversion.
Drug Administration
Modafinil ([(diphenyl-methyl-methyl) sulfinyl]-2 acetamide)
was dissolved in 15 w/v % hydroxypropyl-β-cyclodextrin (β-
HPCD) in (0.9%) saline with sonication and gentle warming
1 h before the experiment (vehicle). In the acute experiment,
micewere treatedwith oneof three doses (25, 50, and100mg/kg)
of modafinil, or vehicle given via intraperitoneal (i.p.) injections
(1 ml/100 g body weight) at the beginning of the dark (active)
period. Doses were chosen based on previous studies [21, 39,
40]. The treatments were performed in a cross-over design (Fig.
S1a, c) in which each mouse received all doses of modafinil in a
randomized order, with a 3-day washout period between treat-
ments. To compare the effect of acute administration ofmodafinil
at different stages of the disease, mice were treated at both 11–
13 weeks of age (early symptomatic stage for R6/2 mice) and at
15–17 weeks of age (mid-late stage). Mice aged 11–13 weeks
and 15–17 weeks are henceforth referred as ‘12 weeks’ or
‘16 weeks’, respectively. In the chronic treatment experiment,
mice were treated orally in the form of edible pills which
contained 64 mg/kg of modafinil in dough, prepared using
wheat, sugar, water, oil, and a small quantity of non-toxic blue
food dye to ensure an equal distribution of the drug [41], or the
equivalent amount of dough. Mice were treated for 9 weeks
starting at 6 weeks of age (Fig. S1b). Mice were randomly
assigned to treatment groups. In the R6/2 group, 10 mice were
treated with modafinil-containing pills and 8 mice were given
pills containing vehicle. We deliberately included more mice in
the modafinil-treatment group as we expected that some R6/2
mice might stop eating the modafinil-containing pills due from
the bitter taste of the drug. In fact, it was the WT mice that
stopped eating the modafinil-containing pills (between the 8th
and 39th days of the treatment period). For this reason, we did
not analyse EEG from theWTmice in the chronic treatment. By
contrast, all R6/2mice ate the pills daily until the end of the study,
and data from all R6/2 mice are therefore included.
Data Analysis
EEG and EMG signals were digitalized using a 256-Hz sam-
pling rate and digitally filtered (EEG, 0.5–100Hz; EMG,
35Hz HPF). Automatic scoring of the EEG traces was per-
formed using SleepSign software (Kissei Comtec,
Matsumoto, Japan). For 10s epochs of the EEG traces, we
distinguished the following vigilance stages: wake, NREMS,
and REMS. The automatic scoring was followed by visual
assessment from experienced scorer, blind to treatment, and
genotype. We performed quantitative EEG (qEEG) analysis
using fast Fourier transformations (FFTs) for consecutive 10s
epochs in the frequency range 0.5–90 Hz (frequency resolu-
tion of 0.5 Hz, Hanning window). Epochs with movement-
induced and other artefacts were discarded. To exclude the
interference noise from the electrical network, values at 49-
and 50-Hz bins were excluded from the qEEG analysis. The
EEG spectral analysis was performed in a state-specific man-
ner by averaging FFT data for each vigilance stage (wakeful-
ness, NREMS, REMS) for the given time period.
Statistics
To evaluate the effect of single doses of modafinil on the amount
of wakefulness, NREMS and REMS for each hour a two-way
double repeated measures ANOVAwas used (hours and doses,
both as repeated variables). For the analysis of different single
doses of modafinil on the summarized vigilance data (1–12 h),
we used two-way repeated measures ANOVAwith the factors:
groups (WT and R6/2 mice aged 12 weeks), age of R6/2 mice
(12 and 16 weeks, repeated), and doses (repeated). The effect of
chronic modafinil treatment on vigilance was analysed at 4 time
points (after 6 or 9 weeks of treatment, and after 1 or 2 weeks of
washout) by two-way repeated measures ANOVA (hours [1–6],
repeated). The effect of modafinil vs. vehicle on the sleep-wake
pattern (number and duration of bouts) of wakefulness, NREMS,
andREMSwas quantified using t tests. A bout was defined as an
episode without interruptions of more than 1 epoch of any other
vigilance stage.
Statistical analyses on qEEG data were performed on raw
EEG power data averaged for the first 2 h of both active and
passive phases, and binned into standard frequency bands:
delta (1–4 Hz), theta (5–9 Hz), alpha (10–14 Hz), and beta
(15–30 Hz) as well as low- (31–60 Hz) and high-frequency
gamma (61–90 Hz). In all cases, two-way repeated measures
1077Wake-Promoting and EEG Spectral Effects of Modafinil After Acute or Chronic Administration in the R6/2...
ANOVAwas used. In the acute study, we evaluated the qEEG
alterations of R6/2 mice vs. WT mice (genotype and frequen-
cy, repeated) and the effect of modafinil vs. vehicle (frequency
and drug, repeated) in each group. In the chronic experiment,
the qEEG effect of modafinil was quantified at each of 4 time
points (after 6 and 9 weeks of treatment, and then 1 and
2 weeks after washout) with factors being drug and frequency
(repeated). For multiple comparisons, Bonferroni post hoc test
was used. The interaction effect of ANOVA (for a frequency
range) was considered significant only if at least 2 x 1Hz
frequency bins showed significant difference compared to
the vehicle group. Results were considered statistically signif-
icant at p < 0.05. All data are shown as mean ± SEM.
Results
Acute Modafinil Has a Similar Wake-Promoting Effect
in Wild-Type and R6/2 Mice at 12 Weeks of Age
Modafinil, given at the beginning of active phase, induced a
dose-dependent increase in the time spent awake in WT mice
(Fig. 1a, drug: F(3,24) = 26.16, p< 0.0001, drug × time interact.:
F(69,552) = 2. 32, p < 0.0001). Modafinil induced wakefulness al-
so in R6/2 mice at both 12weeks (Fig. 1b, drug: F(3,24) = 37.68,
p < 0.0001, drug × time interact.:F(69,552) = 5.72, p< 0.0001) and
16 weeks (Fig. 1c, drug: F(3,24) = 16.61, p < 0.0001, drug × time
interact.:F(69,552) = 2.97, p< 0.0001). At the 100mg/kg dose, the
wake-promoting effect was similar in WT and R6/2 mice aged
12 weeks, lasting for ~ 7 h. Modafinil was less effective in R6/2
mice aged 16 weeks, lasting for ~ 5 h. At lower doses, modafinil
increased the amount of wakefulness by 2 h (for 25mg/kg) or 3 h
(for 50 mg/kg), in both WT mice and R6/2 mice at 12 and
16weeks (Fig. 1a–c).
Analysis of the whole active phase showed that vehicle-
treated R6/2 mice at 12 and 16 weeks spent ~ 23% and ~ 33%
less time awake respectively than WT mice (group: F(3,96) =
58.33, p < 0.0001, Fig. 2a). Lower doses of modafinil (25 or
50 mg/kg) restored the amount of wakefulness in R6/2 mice at
12 and 16 weeks to the WT level, whilst 100 mg/kg caused a
significant increase in wakefulness in 12-week-old R6/2 mice
compared to the WT vehicle-treated mice (Fig. 2a). In parallel
with the wake-promoting effect, modafinil dose-dependently
reduced NREMS in all groups (Fig. 2b, F(3,96) = 62.59,
p < 0.0001), and restored NREMS amount to the WT level
in both 12- and 16-week-old R6/2 mice by both the 25 mg/
kg and 50 mg/kg doses, whilst 100 mg/kg caused a further
decrease. Although modafinil reduced the pathologically in-
creased REMS amount in R6/2 mice at both 12 and 16 weeks
(Fig. 2c, drug: F(3,96) = 36.30, p < 0.0001, drug × group inter-
act.: F(6,96) = 2.51, p = 0.0269), only the 100 mg/kg dose giv-
en to R6/2 mice aged 12 weeks restored REMS to the WT
level.
In the passive phase, modafinil (100 mg/kg) induced a sleep-
consolidating effect in 12-week-old R6/2 mice by increasing both
the total time and the mean duration of episodes in NREMS. This
effect was not seen in WT or 16-week-old R6/2 mice. Modafinil
also had no effect on wakefulness, or the amount and mean dura-
tion of REMS episodes during the passive phase (Table S1).
Fig. 1 The wake-promoting effect of modafinil in R6/2 and wild-type
mice. The hourly amount of the time spent awake across 24 h after
treatment with single doses of modafinil (25, 50, or 100 mg/kg; i.p.,
arrows) is shown compared to vehicle at the beginning of active (dark)
phase in wild-type (a) and R6/2 mice aged 12weeks (b) and 16weeks (c).
The black bar shows the dark period. $, #, and *p < 0.05, compared to the
relevant vehicle in case of the 25, 50, and 100 mg/kg modafinil-treated
groups, respectively. Data are presented as mean ± standard error of mean
(SEM)
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AcuteModafinil Reduces Power of Slow, but Increases
Power of High-Frequency Oscillations
During Wakefulness in R6/2 and WT Mice
To visualize the genotype-specific and modafinil
(100 mg/kg)-induced changes, all EEG power spectra were
normalized to the WT vehicle group (Fig. 3). Modafinil had
differential effect on the spectral power across multiple fre-
quencies. Significant effects of modafinil on the qEEG spectra
(ANOVA ‘treatment’ results for the whole frequency range
and/or results of Bonferroni post hoc tests in case of signifi-
cant treatment × frequency interaction) are shown on the
graphs in Fig. 3. For full statistical analyses, see Table S2–3.
We also analysed EEG power in standard frequency bands.
Administration of modafinil decreased delta (1–4 Hz) power
in WT and R6/2 mice at 12 but not 16 weeks (Fig. 3). Whilst
theta (5–9 Hz) power was suppressed in WT but not R6/2
mice, the peak frequency of theta increased in both WT and
all R6/2 mice (Table S4). Alpha (10–14 Hz) power was re-
duced inWTand R6/2 mice at 16 weeks, but not in R6/2 mice
at 12 weeks. For beta (15–30 Hz) power, the effect varied
across the frequency range. For WT mice, the power at fre-
quencies < 20 Hz decreased significantly, whilst power at fre-
quencies > 29 Hz increased significantly (Fig. 3a). In R6/2
mice at 12 weeks, only the beta power at frequencies of 25–
30 Hz increased in response to modafinil, whilst in R6/2 mice
at 16 weeks, only the power of 29–30 Hz increased (Fig.
3b, c). Gamma power was analysed separated into two bands
(low [31–60 Hz] and high [> 60 Hz]). Gamma power in-
creases progressively as part of the phenotype in R6/2 mice
(see vehicle-treated mice in Fig. 3b, c). Modafinil increased
both low and high gamma power in WT and R6/2 mice at
12 weeks (Fig. 3a, b). In R6/2 mice at 16 weeks, only high
gamma was increased in response to modafinil (Fig. 3c).
Modafinil had no effect on power spectrum in the passive
phase (13–18 h following drug administration) in WT and
R6/2 mice (data not shown).
Acute Modafinil Induces Delta Rebound in NREMS
in WT and R6/2 Mice
Once the wake-promoting effect of modafinil had dissipated
in active phase (Fig. 4d–f), an immediate increase in the
NREMS-delta power (delta rebound) was detected after treat-
ment with 100 mg/kg dose of modafinil in the subsequent 3 h
in WT and in R6/2 mice at 12 and 16 weeks (Fig. 4a–c; WT
mice, F(1.7) = 8.03, p = 0.0253; 12-week-old R6/2 mice,
F(1.7) = 11.59, p = 0.0086; 16-week-old R6/2 mice, F(1.8) =
10.99, p = 0.0106). However, no rebound increase of
NREMS was observed in any of the treatment groups. By
contrast, in the passive phase (during the following 12 h),
the 12-week-old R6/2 mice showed an increase in the amount
of NREMS (t(8) = 2.42, p = 0.0421), and also delta rebound
during NREMS (F(11.88) = 2.95, p = 0.0023) and this was only
in response to the 100 mg/kg modafinil dose (see Table S1).
Modafinil Maintains its Acute Wake-Promoting Effect
Even After 9 Weeks of Chronic Treatment in R6/2 Mice
For the chronic regime, modafinil (64 mg/kg) was adminis-
tered daily for 63 days at the beginning of the active phase
starting at 6 weeks of age. In chronically treated R6/2 mice,
the wake-promoting effect of modafinil in active phase lasted
Fig. 2 The effect of acute modafinil on the amount of sleep-wake stages
in active phase in R6/2 and wild-type mice. Modafinil (25, 50, and
100 mg/kg; i.p.) was administered at the beginning of active phase
(11 am) and the time spent awake (a), in non-rapid eye movement sleep
(NREMS, b), and in rapid eye movement sleep (REMS, c) was measured
in wild-type (WT), and in R6/2 mice aged 12 weeks and 16 weeks. Data
are presented as (mean ± SEM) percent changes in the time spent in each
vigilance stage relative to theWT vehicle group. *p < 0.05 and **p < 0.01
compared to the relevant vehicle treatment; #p < 0.05 and ##p < 0.01
compared to the WT vehicle group
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~ 3 h after both 6 (Fig. 5a; drug effect, F(1,16) = 25.57, p =
0.0001; interaction, F(5,80 = 2.89, p = 0.0188) and 9 weeks of
treatment (Fig. 5a; drug: F(1,16) = 81.32, p < 0.0001,
interaction: F(5,80 = 5.70, p = 0.0002). The increase in wake-
fulness was mostly at the expense of NREMS both after 6
(Fig. 5b, drug: F(1,16) = 26.03, p = 0.0001, interact.: F(5,80 =
2.96, p = 0.0169) and 9 weeks of treatment (drug: F(1,16) =
71.86, p < 0.0001, interaction: F(5,80 = 4.97, p = 0.0005).
Modafinil also suppressed REMS. This effect was more pow-
erful after treatment for 9 weeks (Fig. 5c, drug: F(1,16) = 26.29,
p = 0.0001, interaction: F(5,80) = 6.11, p < 0.0001) than it was
after 6 weeks (Fig. 5c, drug: F(1,16) = 13.30, p = 0.0022).
Following washout, no effect of modafinil on the sleep-wake
pattern was seen (Fig. 5b, d and f) apart from a small effect on
REMS bout duration at 2 weeks after washout (Table S5).
Chronic Modafinil Treatment Differentially
Suppresses the EEG Power in Sleep and Wakefulness
in R6/2 Mice
After 9 weeks of treatment, there was a small but sig-
nificant decrease in theta power in the active phase
(Fig. 6a). Interestingly, in the passive phase, 12 h after
drug administration (Fig. 6b), theta, alpha, and high
gamma power were reduced in the treated mice. After
1 week of drug washout, the reduction in theta power in
passive phase persisted (Fig. 6c, d). Following 2 weeks
of washout, when R6/2 mice were at a late stage of
disease, there were striking differences in EEG power
between modafinil- and vehicle-treated mice in both ac-
tive and passive phases. EEG power in modafinil-treated
mice was significantly lower in theta, alpha, and both
gamma frequency bands (Fig. 6e, f). That is, vehicle-
treated mice showed abnormalities in EEG spectra that
are suppressed in the modafinil-treated group, even
2 weeks after drug treatment stopped.
In NREM sleep, 9 weeks of modafinil treatment reduced
the EEG power of delta, theta, alpha, and beta frequency
bands (Fig. S2a). After 1 week of washout, this effect was
visible but no longer significant (Fig. S2c). After 2 weeks of
washout, the entire NREMS qEEG spectra was increased in
the vehicle-treated R6/2 mice, consistent with progression of
disease. Interestingly, it remained suppressed in the modafinil-
treated mice (Fig. S2e).
In REMS, the power of alpha and both low and high gam-
ma were suppressed after 9 weeks of treatment. This effect
persisted for the 2 weeks of washout. After 2 weeks of wash-
out, the difference between the EEG power of vehicle- and
modafinil-treated R6/2 mice was extensive, affecting all fre-
quency bands apart from delta (Fig. S2b, d and f). Full statis-
tical analyses of the chronic modafinil-induced qEEG effects
are in Table S6–11. Six weeks of treatment induced similar
changes on the qEEG during wakefulness, NREMS, and
REMS to that observed after 9 weeks of treatment (Fig. S3a-
d, and Table S12–13).
Fig. 3 Effects of acute modafinil on the quantitative EEG during
wakefulness in R6/2 and wild-type mice. EEG power from wild-type (WT,
a) and R6/2 mice aged 12 weeks (b) and 16 weeks (c) was averaged in the
first 2 h of the active phase after i.p. vehicle or 100mg/kgmodafinil treatment.
Data (mean ± SEM) were normalized to theWT vehicle group (dashed line).
Changes in the qEEG spectra following acute modafinil treatment was
quantified across the spectrum in standard frequency ranges (δ [1–4Hz], θ
[5–9Hz], α [10–14 Hz], β [15–30 Hz], γ1 [31–60 Hz], and γ2 [61–90 Hz]).
Statistically significant differences (two-way ANOVA and Bonferroni post
hoc comparisons, *p < 0.05) are shown by thick black bars (modafinil vs.
vehicle treatments) and by thin black bars (vehicle treatedWT vs. R6/2 mice)
above the graphs
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Discussion
Herewe report for the first time that modafinil improves sleep-
wake pattern and abnormalities of qEEG in R6/2 HD mice.
Acute modafinil restores the amount of wakefulness and
NREMS to the WT level, even in the late stage of disease.
The wake-promoting effect of modafinil is reflected as a de-
crease in power of low (< 12 Hz) and an increase in power of
high (> 24 Hz)-frequency EEG oscillations. Acute modafinil
reduces the pathologically increased REMS in active phase
and consolidates sleep in the passive phase in R6/2 mice. In
chronically treated R6/2 mice, modafinil maintains its acute
wake-promoting and REMS-reducing effect. Moreover, it
causes long-lasting suppression of EEG power including the
pathologically increased gamma seen in R6/2 mice.
The sleep-wake cycle is regulated by complex homeostatic
and circadian processes [42], and involves several cortical and
subcortical structures [43–45]. In HD patients, although the
early neurodegeneration affects the medium-sized spiny neu-
rons in the striatum, eventually neurodegeneration is wide-
spread, affecting multiple parts of the brain including the cir-
cuits and neurotransmitter systems involved in the regulation
of sleep and wake [46, 47]. Together, these changes probably
contribute to the sleep disturbance in HD. In R6/2 mice, the
sleep-wake abnormalities are characterised by a breakdown in
circadian regulation with an increase in wake during the pas-
sive phase and sleep during the active phase [11, 12]. Here,
acute modafinil promoted wakefulness at the expense of sleep
in a similar manner in both WT and R6/2 mice, although in
R6/2 mice at 16 weeks, the response to the highest dose
(100 mg/kg) was shorter than that seen at 12 weeks. The
wake-promoting effect of the daily doses of modafinil
persisted in the chronically treated R6/2 mice, suggesting that
there was no desensitization to the effect of modafinil.
Together these data suggest that the circuits and neurotrans-
mitter systems crucial for the generation and maintenance of
wakefulness [45] remain intact in R6/2 mice, although they
show some changes in sensitivity with the progression of the
disease. Modafinil consolidated the fragmented NREMS seen
in R6/2 mice in the passive phase. This effect is particularly
relevant, since it has been hypothesised that being unable to
sustain wakefulness in the active phase contributes to poor
sleep in HD [3]. Thus, although modafinil is wake-promoting,
it may also have beneficial knock-on effects on sleep. A key
feature of pathological changes in HD mice is that the amount
of REMS increases progressively [11, 12]. Interestingly, acute
modafinil had much less effect on REMS than it did on
NREMS, with only the 100 mg/kg dose restoring REMS to
the WT level, and only at 12 weeks. We speculate that the
networks involved in the regulation of REMS are less sensi-
tive to the effect of modafinil compared to those circuits in-
volved in the regulation of wakefulness/NREMS.
Changes in the qEEG spectra following acute modafinil
reflect its wake-promoting action. The effects of modafinil
on the qEEG spectra were diverse and depended upon both
the age of the mice and the dose regime. As shown previously
in WT mice [39], acute modafinil reduced delta power in 12-
week-old R6/2 mice, but not at 16 weeks of age, suggesting
Fig. 4 Delta power changes
induced by modafinil during non-
rapid eye movement sleep
(NREMS) in R6/2 and wild-type
mice. Delta power (1–4 Hz) was
averaged for each hour after the
injection of vehicle or modafinil
(100 mg/kg, i.p.) at the beginning
of active phase in wild-type (WT,
a) or in R6/2 mice aged 12 weeks
(b) and 16 weeks (c). Note that
due to the robust NREMS-
decreasing effect of modafinil (1–
7 h) in WT and in R6/2 mice at
12 weeks of age (d and e,
respectively), as well as (1–5 h) at
16 weeks of age (f), the average
delta power data for these hours
were not evaluated statistically.
The vertical dashed lines show the
end of the wake-promoting effect
in each group. The arrows show
the beginning of the ‘delta
rebound’. Data are presented as
mean ± SEM. *p < 0.05,
compared to the relevant vehicle
group
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that cortical and thalamic circuits important for the generation
of delta oscillations [48] are still intact in the young symptom-
atic age of R6/2 mice. In HD patients, the subjective feeling of
sleepiness, reflected by increased delta power in wakefulness,
is a progressive feature of the disease [6, 49, 50]. Thus, we can
speculate that daytime sleepiness in HD may be improved via
decreasing delta power by modafinil. The idea that these cir-
cuits are still intact in the R6/2 mice is supported by the emer-
gence of delta rebound during NREMS. Delta power in
NREMS is an indicator of homeostatic sleep drive that in-
creases with accumulating sleep pressure [42]. Delta rebound
in R6/2 mice is blunted following sleep deprivation [12], due
to the impaired ability of the cortex to generate and propagate
delta oscillations, possibly as a result of hyperexcitability of
cortical pyramidal neurons that has been reported in R6/2
mouse brain slices [51]. Thus, its emergence after modafinil-
induced wakefulness is particularly interesting since it sup-
ports the idea that, at least at 12 weeks, cortical circuits regu-
lating delta generation are intact, but not operating normally in
the untreated R6/2 mice.
Acute modafinil increased beta, low, and high gamma pow-
er in WT and also in 12-week-old R6/2 mice in line with
studies reporting EEG-desynchronising effects of modafinil
[52, 53]. In HD, increased beta and gamma power are pheno-
typic markers in both human [3] and (R6/2 and Q175) mouse
models of HD [11, 12, 16]. The effect of acute modafinil on
R6/2 mice was seen over and above the pathologically in-
creased power seen in those spectral ranges. However, by
16 weeks, only the power of high gamma and a narrow band
of beta was increased significantly, suggesting that by this age
the neuronal circuits generating beta and low gamma frequen-
cies in R6/2 mice had lost their sensitivity to modafinil.
Fig. 5 The effect of chronic
treatment with modafinil on the
pattern of sleep-wake cycle in R6/
2 mice. Modafinil (64 mg/kg, per
os) significantly changed the
amount of wakefulness (a), non-
rapid eye movement sleep
(NREMS, b), and rapid eye
movement sleep (REMS, c) after
6 and 9 weeks of treatment,
although the effect reversed
gradually following 1 or 2 weeks
of washout (b, d, and f,
respectively). The arrows indicate
the time of the treatment at the
beginning of active phase. Data
are presented as mean ± SEM.
&p < 0.01 after 6 weeks of
treatment, and *p < 0.05 and
**p < 0.01 after 9 weeks of
treatment, compared to the
relevant vehicle groups
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Although 9 weeks of chronic modafinil treatment produced no
striking changes on the qEEG in active phase, passive phase
data revealed significant changes. For example, whilst high
gamma power of vehicle-treated R6/2 mice increased patho-
logically, in the chronic modafinil-treated mice the abnormally
high gamma was suppressed. Moreover, after 2 weeks of
washout, suppression of both the low and high gamma power
persisted in the previously treated mice. Since in human HD
increased gamma power has been suggested to be a compo-
nent of the uncontrollable choreatic movements [54], reduc-
tion of this might be beneficial in HD.
The effect of chronic modafinil on beta oscillations was
particularly interesting, as despite chronic modafinil having
no effect on beta power, after 2 weeks washout, the abnormal
changes in beta did not emerge in the chronic modafinil group.
This suggests that chronic modafinil might have supressed the
pathological remodelling of circuits responsible for the gener-
ation of abnormal beta oscillations. The differential response
of beta, low, and high gamma to the effect of acute modafinil
in 12- and 16-week-old R6/2 mice also supports the idea that
progressive neurodegenerative changes modify the sensitivity
of these networks differentially. Also, these results suggest
Fig. 6 The effect of chronic
modafinil treatment on the
quantitative
electroencephalography (EEG) in
R6/2 mice measured during
wakefulness. EEG spectra of
vehicle- (solid black line) or
modafinil (solid blue line)-treated
groups during the first 2 h of the
active (a, c, and e) and the passive
phase (b, d, and f), after 9 weeks
of treatment (a and b) and
following 1 week (c and d) or
2 weeks of washout (e and f).
Data are presented as mean ±
SEM in 1 Hz bins, normalized to
the WT vehicle group (dashed
line). Changes in the qEEG
spectra following chronic
modafinil treatment were
quantified across the spectrum in
standard frequency ranges (δ [1–
4Hz], θ [5–9Hz],α [10–14Hz],β
[15–30 Hz], γ1 [31–60 Hz], and
γ2 [61–90 Hz]). Statistically
significant differences (two-way
ANOVA and Bonferroni post hoc
comparisons, *p < 0.05) are
shown by black bars (modafinil
vs. vehicle treatments) above the
graphs
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that circuits giving rise to beta and gamma oscillations are
modulated independently. Indeed, in humans, suppression of
beta power has been suggested to play an antikinetic role in
movement regulation [55, 56], whilst the amplitude of low
and high gamma oscillations is modulated related to the phase
of the gait cycle [56].
In both HD patients [49] and R6/2 mice [12], there is a
pathological decrease in theta power as well as a decrease in
the peak frequency of theta oscillations in the wake EEG. As
seen in WT mice [39], acute modafinil increased the peak
theta frequency in R6/2 mice at both 12 and 16 weeks, sug-
gesting that, as with the circuits generating gamma, those gen-
erating theta remain responsive to the acute effect of
modafinil. Theta is a fundamental brain rhythm mediating
the information flow through the hippocampus, thalamus,
and frontal cortex [57] that has been linked to cognitive func-
tions in both rodents [58] and humans [59]. Thus, restoring or
further increasing the frequency of theta may mediate a ben-
eficial effect of modafinil on cognition in HD.
In the EEG signature of HD, changes in alpha power may
reflect dysfunction of thalamic networks [49, 60]. The change
in alpha power is usually a decrease, however, increased alpha
has also been reported as an electrophysiological correlate of
sustained motor activity during NREMS in HD patients [61].
By 16 weeks, the pathological decrease in alpha power
emerged in R6/2 mice. Interestingly, acute modafinil de-
creased it further at this age. The suppressive effect of
modafinil on alpha was also significant in the chronic treat-
ment group and was maintained for 2 weeks of washout. As
alpha is linked to a number of different brain functions, in-
cluding sensory and memory processes (reviewed in [62]),
this needs further studies to clarify how sustained suppression
of alpha might affect these behavioural correlates.
Another property of modafinil that may contribute to a
beneficial effect on sleep is the amelioration of neuroin-
flammation in sleep-deprived rats by reducing the level of
pro-inflammatory cytokines [63]. This is particularly rel-
evant, as the accumulation of pro-inflammatory cytokines
has been demonstrated to induce neuroinflammation in
HD [64]. Moreover, modafinil has been shown to promote
hippocampal neurogenesis [65] and synaptic plasticity
[66, 67], and its possible neuroprotective role has also
been reported against methamphetamine induced striatal
toxicity [68]. Thus, there are multiple mechanisms where-
by modafinil might be beneficial in HD.
It is clear that modafinil has a complex action on different
components of the qEEG and that not all of the actions of
modafinil can be explained by our current understanding of
the circuitry underlying HD. It is possible that some of the
qEEG changes in the R6/6 mice are compensatory and there-
fore it may not be desirable to reverse them. What has
emerged from our study is that different parts of the abnormal
EEG in R6/2 mice are modulated differentially by modafinil.
Furthermore, some of these effects are sustained long after the
drug would be predicted to have disappeared from the system.
It is possible that chronic modafinil treatment prevented path-
ological changes in the R6/2 mouse brain. Alternatively,
modafinil may have modulated other changes occurring in
the R6/2 brain such that even after cessation of the treatment,
lasting benefits were seen. That is, modafinil may be masking
the ongoing pathology. Regardless of the underlying mecha-
nism, it is interesting that the beneficial effects of modafinil
persisted 2 weeks after the treatment. The complexities of
modafinil action are not entirely unexpected. All these trans-
mitter systems are involved in regulation of sleep and wake
[45] as well as in HD pathology (for references, see [1]).
Indeed, it is not known precisely which pathways generate
HD symptoms such as motor, cognitive, and sleep disorder.
The complexity of the pathways modulating behaviour and
their interactions are likely to be increased in the dynamically
degenerating brain. Studying the effects of a drug such as
modafinil on EEG may give some insight into this
interrelationship.
Limitation of the Study
Our data show that chronic modafinil treatment evoked long-
lasting changes on the EEG powers in R6/2 mice, suggesting
that modafinil had beneficial effects. However, given that we
were not able to collect parallel data fromWTmice, we cannot
determine if these changes are specific to the R6/2 mice, nor
can we say anything about the possible long-term effect on
EEG spectra of WT mice.
Conclusions
Modafinil has acute beneficial effects on the sleep-wake
pattern of R6/2 mice that suggests that it may be useful
clinically for treating sleep-wake disorder in HD.
Chronic modafinil induced both short- and long-lasting
changes in qEEG and prevents the manifestation of
pathological changes in the EEG spectrum. Whilst
modafinil acted clearly as a wake-promoting agent in
R6/2 mice, its complex action on qEEG shows that
modafinil differentially affects brain systems likely to
be involved not only in the regulation of sleep and
wakefulness but also in other higher brain functions. A
better understanding of these actions is needed to use
modafinil to best effect in patients with complex neuro-
logical disorders.
Acknowledgements We thank Drs Zhiguang Zheng, Janos Varga, and
Sandor Kantor for their technical assistance and Dr. Nigel Wood for
proofreading and for the valuable discussions.
1084 Vas et al.
Funding Information This work was supported by a grant from the CHDI
Inc.
Compliance with Ethical Standards
Conflict of Interest The authors declare that they have no conflict of
interest.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons licence, and indicate if
changes weremade. The images or other third party material in this article
are included in the article's Creative Commons licence, unless indicated
otherwise in a credit line to the material. If material is not included in the
article's Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will
need to obtain permission directly from the copyright holder. To view a
copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References
1. Bates and Tabrizi and J. Huntington’s Disease, 4th ed. https://doi.
org/10.1093/med/9780199929146.001.0001
2. Goodman AOG, Morton AJ, Barker RA. Identifying sleep distur-
bances in Huntington’s disease using a simple disease-focused
questionnaire. PLoS Curr 2010;2:RRN1189
3. Lazar AS, Panin F, Goodman AOG, et al. Sleep deficits but no
metabolic deficits in premanifest Huntington’s disease. Ann
Neurol 2015;78:630–648
4. Piano C, Losurdo A, Della Marca G, et al. Polysomnographic
Findings and Clinical Correlates in Huntington Disease: A Cross-
Sectional Cohort Study. Sleep 2015;38:1489–1495
5. Arnulf I, Nielsen J, Lohmann E, et al. Rapid eye movement sleep
disturbances in Huntington disease. Arch Neurol 2008;65:482–488
6. Videnovic A, Leurgans S, Fan W, Jaglin J, Shannon KM. Daytime
somnolence and nocturnal sleep disturbances in Huntington dis-
ease. Park Relat Disord 2009;5:471–474
7. Piano C, Mazzucchi E, Bentivoglio AR, et al. Wake and Sleep EEG
in Patients with Huntington Disease. Clin EEG Neurosci 2017;48:
60–71
8. Aziz NA, Anguelova G V., Marinus J, Lammers GJ, Roos RAC.
Sleep and circadian rhythm alterations correlate with depression
and cognitive impairment in Huntington’s disease. Park Relat
Disord 2010;16:345–350
9. Morton AJ. Circadian and sleep disorder in Huntington’s disease.
Exp Neurol 2013;243:34–44
10. Nguyen L, Bradshaw JL, Stout JC, Croft RJ, Georgiou-Karistianis
N. Electrophysiological measures as potential biomarkers in
Huntington’s disease: Review and future directions. Brain Res
Rev 2010;64:177–94
11. Kantor S, Szabo L, Varga J, Cuesta M, Morton AJ. Progressive
sleep and electroencephalogram changes in mice carrying the
Huntington’s disease mutation. Brain 2013;136:2147–2158
12. Fisher SP, Black SW, Schwartz MD, et al. Longitudinal analysis of
the electroencephalogram and sleep phenotype in the R6/2 mouse
model of Huntington’s disease. Brain 2013;136:2159–2172
13. Pignatelli M, Lebreton F, Cho YH, Leinekugel X. “Ectopic” theta
oscillations and interictal activity during slow-wave state in the R6/
1 mouse model of Huntington’s disease. Neurobiol Dis 2012;48:
409–417
14. Lebreton F, Cayzac S, Pietropaolo S, Jeantet Y, Cho YH. Sleep
physiology alterations precede plethoric phenotypic changes in
R6/1 Huntington’s disease mice. PLoS One 2015;10:e0126972
15. Loh DH, Kudo T, Truong D, Wu Y, Colwell CS. The Q175 Mouse
Model of Huntington’s Disease Shows Gene Dosage- and Age-
Related Decline in Circadian Rhythms of Activity and Sleep.
PLoS One 2013;8:e69993
16. Rothe T, Deliano M, Wójtowicz AM, et al. Pathological gamma
oscillations, impaired dopamine release, synapse loss and reduced
dynamic range of unitary glutamatergic synaptic transmission in the
striatum of hypokinetic Q175 Huntington mice. Neuroscience
2015;311:519–538
17. Fisher SP, Schwartz MD, Wurts-Black S, et al. Quantitative
Electroencephalographic Analysis Provides an Early-Stage
Indicator of Disease Onset and Progression in the zQ175 Knock-
In Mouse Model of Huntington’s Disease. Sleep 2016;39:379–91
18. Mangiarini L, Sathasivam K, Seller M, et al. Exon I of the HD gene
with an expanded CAG repeat is sufficient to cause a progressive
neurological phenotype in transgenic mice. Cell 1996;87:493–506
19. Lione LA, Carter RJ, Hunt MJ, et al. Selective discrimination learn-
ing impairments in mice expressing the human Huntington’s dis-
ease mutation. J Neurosci 1999;19:10428–10437
20. Carter RJ, Lione LA, Humby T, et al. Characterization of progres-
sive motor deficits in mice transgenic for the human Huntington’s
disease mutation. J Neurosci 1999;19:3248–3257
21. Pallier PN,MortonAJ.Management of sleep/wake cycles improves
cognitive function in a transgenic mouse model of Huntington’s
disease. Brain Res 2009;1279:90–8
22. Wulff K, Gatti S, Wettstein J, Foster R. Sleep and circadian rhythm
disruption in psychiatric and neurodegenerative disease. Nat Rev
Neurosci 2010;11:589–99
23. Baker CR, Domínguez D JF, Stout JC, et al. Subjective sleep prob-
lems in Huntington’s disease: A pilot investigation of the relation-
ship to brain structure, neurocognitive, and neuropsychiatric func-
tion. J Neurol Sci 2016;364:148–53
24. Blackwell AD, Paterson NS, Barker RA, Robbins TW, Sahakian
BJ. The effects of modafinil onmood and cognition in Huntington’s
disease. Psychopharmacology (Berl) 2008;199:29–36
25. Bat t l eday RM, Brem AK. Modaf in i l fo r cogni t ive
neuroenhancement in healthy non-sleep-deprived subjects: A sys-
tematic review. Eur Neuropsychopharmacol 2015;25:1865–81
26. Herzog-Krzywoszanska R, Krzywoszanski L. Sleep Disorders in
Huntington’s Disease. Front Psychiatry 2019;10:221
27. Thorpy MJ. Update on Therapy for Narcolepsy. Curr Treat Options
Neurol 2015;17:347
28. Rodrigues TM, Caldas AC, Ferreira JJ. Pharmacological interven-
tions for daytime sleepiness and sleep disorders in Parkinson’s dis-
ease: Systematic review and meta-analysis. Park Relat Disord
2016;27:25–34
29. Minzenberg MJ, Carter CS. Modafinil: A review of neurochemical
actions and effects on cognition. Neuropsychopharmacology
2008;33:1477–502
30. Murillo-Rodríguez E, Barciela Veras A, Barbosa Rocha N, Budde
H, Machado S. An Overview of the Clinical Uses, Pharmacology,
and Safety of Modafinil. ACS Chem Neurosci 2018;9:151–158
31. Randall DC, Shneerson JM, File SE. Cognitive effects of modafinil
in student volunteers may depend on IQ. Pharmacol Biochem
Behav 2005;82:133–9
32. Müller U, Rowe JB, Rittman T, et al. Effects of modafinil on non-
verbal cognition, task enjoyment and creative thinking in healthy
volunteers. Neuropharmacology 2013;64:490–495
33. Minzenberg MJ, Yoon JH, Cheng Y, Carter CS. Sustained
Modafinil Treatment Effects on Control-Related Gamma
Oscillatory Power in Schizophrenia. Neuropsychopharmacology
2016;41:1231–40
1085Wake-Promoting and EEG Spectral Effects of Modafinil After Acute or Chronic Administration in the R6/2...
34. Lees J, Michalopoulou PG, Lewis SW, et al. Modafinil and cogni-
tive enhancement in schizophrenia and healthy volunteers: The ef-
fects of test battery in a randomised controlled trial. Psychol Med
2017;47:2358–2368
35. Turner D. A review of the use of modafinil for attention-deficit
hyperactivity disorder. Expert Rev Neurother 2006;6:455–68
36. Abolfazli R, Hosseini M, Ghanizadeh A, et al. Double-blind ran-
domized parallel-group clinical trial of efficacy of the combination
fluoxetine plus modafinil versus fluoxetine plus placebo in the treat-
ment of major depression. Depress Anxiety 2011;28:297–302
37. Rasetti R, Mattay VS, Stankevich B, et al. Modulatory effects of
modafinil on neural circuits regulating emotion and cognition.
Neuropsychopharmacology 2010;35:2101–9
38. Paulsen JS, Nehl C, Hoth KF, et al. Depression and stages of
Huntington’s disease. J Neuropsychiatry Clin Neurosci 2005;17:
496–502
39. Willie JT, Renthal W, Chemelli RM, et al. Modafinil more effec-
tively induces wakefulness in orexin-null mice than in wild-type
littermates. Neuroscience 2005;130:983–95
40. Wisor JP, Eriksson KS. Dopaminergic-adrenergic interactions in the
wake promoting mechanism of modafinil. Neuroscience 2005;132:
1027–34
41. Wood NI, Glynn D, Morton AJ. “Brain training” improves cogni-
tive performance and survival in a transgenic mouse model of
Huntington’s disease. Neurobiol Dis 2011;42:427–37
42. Borbely AA. A two process model of sleep regulation. Hum
Neurobiol 1982;1:195–204
43. Saper CB, Chou TC, Scammell TE. The sleep switch:
Hypothalamic control of sleep and wakefulness. Trends Neurosci
2001;24:726–31
44. Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep
and circadian rhythms. Nature 2005;437:1257–63
45. Scammell TE, Arrigoni E, Lipton JO. Neural Circuitry of
Wakefulness and Sleep. Neuron 2017;93:747–765
46. Vonsattel JP, Myers RH, Stevens TJ, et al. Neuropathological clas-
sification of huntington’s disease. J Neuropathol Exp Neurol
1985;44:559–77
47. Rosas HD, Salat DH, Lee SY, et al. Complexity and heterogeneity:
What drives the ever-changing brain in Huntington’s disease? Ann
N YAcad Sci 2008;1147:196–205
48. Amzica F, SteriadeM. Electrophysiological correlates of sleep delta
waves. Electroencephalogr Clin Neurophysiol 1998;107:69–83
49. Bylsma FW, Peyser CE, Folstein SE, Ross C, Brandt J. EEG power
spectra in huntington’s disease: Clinical and neuropsychological
correlates. Neuropsychologia 1994;32:137–50
50. Painold A, Anderer P, Holl AK, et al. Comparative EEG mapping
studies in Huntington’s disease patients and controls. J Neural
Transm 2010;117:1307–1318
51. Cummings DM, Andre VM, Uzgil BO, et al. Alterations in Cortical
Excitation and Inhibition in GeneticMouseModels of Huntington’s
Disease. J Neurosci 2009;29:10371–86
52. Hasan S, Pradervand S, Ahnaou A, et al. How to keep the brain
awake the complex molecular pharmacogenetics of wake promo-
tion. Neuropsychopharmacology 2009;34:1625–40
53. Chen CR, Yang SR, Liu YY, et al. Roles of Adrenergic α1 and
Dopamine D1 and D2 Receptors in the Mediation of the
Desynchronization Effects of Modafinil in a Mouse EEG
Synchronization Model. PLoS One 2013;8:e76102
54. Ferrea S, Groiss SJ, Elben S, et al. Pallidal deep brain stimulation in
juvenile Huntington’s disease: local field potential oscillations and
clinical data. J Neurol 2018;265:1573–1579
55. Jenkinson N, Brown P. New insights into the relationship between
dopamine, beta oscillations and motor function. Trends Neurosci
2011;34:611–8
56. SeeberM, Scherer R,Wagner J, Solis-Escalante T,Müller-Putz GR.
EEG beta suppression and low gamma modulation are different
elements of human upright walking. Front Hum Neurosci 2014;8:
485
57. Kirk IJ, Mackay JC. The role of theta-range oscillations in
synchronising and integrating activity in distributed mnemonic net-
works. Cortex 2003;39:993–1008
58. Vinogradova OS. Expression, control, and probable functional sig-
nificance of the neuronal theta-rhythm. Prog Neurobiol 1995;45:
523–83
59. Raghavachari S, Kahana MJ, Rizzuto DS, et al. Gating of Human
Theta Oscillations by a Working Memory Task. J Neurosci
2001;21:3175–83
60. Bellotti R, De Carlo F, Massafra R, de Tommaso M, Sciruicchio V.
Topographic classification of EEG patterns in Huntington’s disease.
Neurol Clin Neurophysiol 2004;2004:37
61. Piano C,Mazzucchi E, Bentivoglio AR, et al. Wake and Sleep EEG
in Patients With Huntington Disease An eLORETA Study and
Review of the Literature. Clin EEG Neurosci 2016;48:60–71
62. Klimesch W, Sauseng P, Hanslmayr S. EEG alpha oscillations: The
inhibition-timing hypothesis. Brain Res Rev 2007;53:63–88
63. Wadhwa M, Chauhan G, Roy K, et al. Caffeine and Modafinil
Ameliorate the Neuroinflammation and Anxious Behavior in Rats
during Sleep Deprivation by Inhibiting the Microglia Activation.
Front Cell Neurosci 2018;12:49
64. Staal RGW, Möller T. Neuroinflammation in Huntington’s disease.
In: Neuroinflammation Neurodegener. Springer New York, pp
179–197
65. Brandt MD, Ellwardt E, Storch A. Short- and long-term treatment
with modafinil differentially affects adult hippocampal
neurogenesis. Neuroscience 2014;278:267–275
66. Rao Y, Liu ZW, Borok E, et al. Prolonged wakefulness induces
experience-dependent synaptic plasticity in mouse hypocretin/
orexin neurons. J Clin Invest 2007;117:4022–33
67. TsanovM, Lyons DG, Barlow S, González Reyes RE, O’Mara SM.
The psychostimulant modafinil facilitates water maze performance
and augments synaptic potentiation in dentate gyrus.
Neuropharmacology 2010;59:9–19
68. Raineri M, González B, Rivero-Echeto C, et al. Differential Effects
of Environment-Induced Changes in Body Temperature on
Modafinil’s Actions Against Methamphetamine-Induced Striatal
Toxicity in Mice. Neurotox Res 2015;27:71–83
Publisher’s Note Springer Nature remains neutral with regard to juris-
dictional claims in published maps and institutional affiliations.
1086 Vas et al.
